Chargement en cours...
Diabetes prevention: Can insulin secretagogues do the job?
The recent Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial reported that nateglinide, a non-sulfonylurea insulin secretagogue, failed to prevent progression from impaired glucose tolerance to diabetes. In order to determine the beneficial effect of insulin...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2010
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3746508/ https://ncbi.nlm.nih.gov/pubmed/21185798 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pcd.2010.11.002 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|